checkAd
    Startseite > Aktien > Sorrento Therapeutics > Nachrichten
    Sorrento Therapeutics Aktie
    0,0150
     
    USD
    +7,14 %
    +0,0010 USD
    Letzter Kurs 02:10:00 Nasdaq OTC
    ISIN: US83587F2020 · WKN: A1W8DY · SYM: SRNE · USA

    Neueste Nachrichten

    Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
    12.09.23 · globenewswire · Sorrento Therapeutics
    Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
    07.09.23 · globenewswire · Sorrento Therapeutics
    Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders
    27.07.23 · globenewswire · Sorrento Therapeutics
    Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study
    05.07.23 · globenewswire · Sorrento Therapeutics
    Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19
    26.06.23 · globenewswire · Sorrento Therapeutics
    Sorrento Therapeutics, Inc. announces a $4.6 Million U.S. Government contract from the NIAID for a Sensitive, Reusable, and Rapid Diagnostic Platform for Pandemic Preparedness
    13.06.23 · globenewswire · Sorrento Therapeutics
    Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the
    05.06.23 · globenewswire · Sorrento Therapeutics